Spanish Biotech PharmaMar Faces Sharp Selloff as Analysts Cut Price Targets and Short Interest Resurfaces
PharmaMar experienced an 11.8% stock decline, prompting analysts to lower their price targets and short-sellers to increase their activity against the Spanish biotechnology company.